Royal Infirmary Of Edinburgh

CellProthera Initiates Long-Term Study of ProtheraCytes for Acute Myocardial Infarction

8 months ago

• CellProthera has begun the PERFECT study, a 10-year observational follow-up to assess ProtheraCytes' long-term safety and efficacy after acute myocardial infarction. • The study will monitor biological markers like NT-proBNP and evaluate patients' clinical status, comparing them to those receiving standard care. • Initial EXCELLENT trial results showed ProtheraCytes improved prognostic markers, suggesting an anti-remodeling effect on cardiac tissue. • This research aims to confirm ProtheraCytes' ability to regenerate and repair heart tissue, potentially reducing the high mortality rate associated with post-AMI complications.